Fenwick represented Amyris, Inc. (NASDAQ: AMRS), the industrial bioscience company, in its offering of $57.6 million aggregate principal amount of the Company’s 9.5% Convertible Senior Notes due 2019. The notes were sold only to qualified institutional buyers and institutional accredited investors in a private placement.
The Fenwick transaction team included corporate partners Daniel Winnike and David Michaels and corporate associates Faisal Rashid, Priscila Bastazin, Ryan McRobert and Seth Popick.